Family-Based Treatment for Type 1 Diabetes (FBT for T1D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05756361
Recruitment Status : Not yet recruiting
First Posted : March 6, 2023
Last Update Posted : March 6, 2023
Sponsor:
Information provided by (Responsible Party):
Teresa Quattrin, University at Buffalo

Brief Summary:
Type 1 Diabetes carries high burden for affected youth and their families. Advances in insulin therapy and technology have been associated with increased obesity with 1/3 adolescents being overweight/obese. Since obesity runs in families and carries risk for poor outcomes psychologically and medically, the investigators are adapting our successful evidence-based Family Based Treatment for hybrid delivery to improve obesity and metabolic control in the affected youth and improve obesity and related co-morbidities in their parents.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Obesity, Childhood Overweight Comorbidities and Coexisting Conditions Behavioral: Family-Based Treatment for T1D Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Family-Based Approach to Treat Obesity and Its Co-morbidities in Youth With Type 1 Diabetes (T1D) and Their Parents
Estimated Study Start Date : March 20, 2023
Estimated Primary Completion Date : March 31, 2024
Estimated Study Completion Date : December 31, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 20 Child-Parent Dyads
Family-Based Behavioral Treatment
Behavioral: Family-Based Treatment for T1D
Our FBT curriculum, which has been delivered successfully in the specialty and primary care settings, has 3 components: 1. Meal planning including quality of carbohydrates and glycemic index for both parents and children while ensuring that youth have a balanced meal plan with adequate amounts of carbohydrates for optimal growth. Our FBT has a focus on "Food Literacy" including healthy food selection and sourcing of affordable healthy food, food preparation and preplanning, social engagement tailoring the meal plan to the needs to the family in socio cultural appropriate way and also feasibility based on logistics and economic aspects; 2. Physical activity (PA) component with shaping strategy to allow for a progressive shaping of easy PA starting, if needed, with as little as with 10 minutes of walking/day and strategies to incorporate PA in daily routines, family, and social activities; 3. Extensive behavioral component which has been shown to be very powerful in obesity treatment




Primary Outcome Measures :
  1. Change in Weight for parent and child [ Time Frame: Baseline, 3 and 6 months ]
    Participants will be given Body Trace Weight Scales and will weigh themselves twice per week.


Secondary Outcome Measures :
  1. Change in insulin dosing [ Time Frame: baseline, 3 and 6 months ]
    Metrics will be obtained through Insulin pumps

  2. In parents, change in severity of obesity co-morbidities [ Time Frame: baseline, 3 and 6 months ]
    Participants will be given Body Trace Weight Scales and will weigh themselves twice per week. Parent co-morbidities will be tracked on a sheet

  3. Change in HbA1c [ Time Frame: baseline, 3 and 6 months ]
    Metrics will be obtained through Continuous Glucose Monitor

  4. Change in time in range (TIR) - that is in optimal glycemic range [ Time Frame: baseline, 3 and 6 months ]
    Metrics will be obtained through Continuous Glucose Monitor

  5. In parents, change in medication dosing [ Time Frame: baseline, 3 and 6 months ]
    Parent medications will be tracked on a sheet.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • T1D of 12 or more months duration
  • Age 6-17-years
  • Presence of overweight/obesity
  • Youth uses a pump for insulin delivery and a continuous glucose monitoring device to monitor glycemic levels
  • Youth has one parent with overweight/obesity willing to participate in the program

Exclusion Criteria:

  • Child:

    • Chronic conditions other than T1D
    • Other autoimmune conditions other then T1D or autoimmune thyroiditis.
    • Medications that can affects weight, such as medications used to treat Attention Deficit Disorder or high dose steroids used to treat asthma.
    • Depression symptoms by standard of care Patient Health Questionnaire (PHQ) 9 in the child or parent
    • Inability to perform at least mild physical activity such as walking
    • Child with handicap (such as developmental delay or deafness) that would prevent him/her from benefitting from counseling in person and/or remotely Participating parent with
    • symptoms of depression assessed by standard of care PHQ
    • autoimmune disorders other than T1D or autoimmune thyroiditis
    • Participating parents with chronic disorder that is treated with medications that interfere with weight loss or are preventing him/her from performing at least mild physical activity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05756361


Contacts
Layout table for location contacts
Contact: Teresa Quattrin, MD (716) 480-3185 tquattrin@upa.chob.edu
Contact: Andy Strohmeier, M.Ed. (716) 480-3185 awstrohm@buffalo.edu

Sponsors and Collaborators
University at Buffalo
Layout table for additonal information
Responsible Party: Teresa Quattrin, Principal Investigator, University at Buffalo
ClinicalTrials.gov Identifier: NCT05756361    
Other Study ID Numbers: STUDY00006622: FBT for T1D
First Posted: March 6, 2023    Key Record Dates
Last Update Posted: March 6, 2023
Last Verified: February 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Obesity
Diabetes Mellitus, Type 1
Pediatric Obesity
Overweight
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Overnutrition
Nutrition Disorders
Body Weight
Autoimmune Diseases
Immune System Diseases